RenovoRx (Nasdaq:RNXT) announced that it entered into a strategic research collaboration with Imugene to optimize oncolytic virus therapy delivery. Utilizing RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform), the companies hope to enhance the treatment of difficult-to-access tumors. “Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally […]
